Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561360 · ClinicalTrials.gov registry record · Phase 2
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
A Phase 2 study of Hairy Cell Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 10
- Study locations
NCT06561360: Recruiting Phase 2 study of Hairy Cell Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06561360 is a Phase 2 study of Hairy Cell Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 86 participants, above the 67-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (28% higher). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06561360, a Phase 2 study of Hairy Cell Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 10
- Study locations
Study Summary
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
Primary Outcome
per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Cladribine
- DRUG Rituximab
- DRUG Vemurafenib
Study Locations (10)
New York
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Cancer Center - Rochester
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2027-09-09 |
| Phase | Phase 2 |
What NCT06561360 shows while recruiting
NCT06561360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 67-participant average among 15 other Hairy Cell Leukemia trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Hairy Cell Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT06561360 lists 10 locations in 5 states (New York, New Jersey, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06561360 about?
NCT06561360 is a clinical study titled "A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)". The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obin...
What is the current status of trial NCT06561360?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2024-09-09. Estimated completion is 2027-09-09.
What conditions does trial NCT06561360 study?
This clinical trial studies the following conditions: Hairy Cell Leukemia.
What interventions are being tested in trial NCT06561360?
The interventions under investigation include: Obinutuzumab (DRUG), Cladribine (DRUG), Rituximab (DRUG), Vemurafenib (DRUG).
Who is sponsoring clinical trial NCT06561360?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561360 being conducted?
This trial has 10 study locations across Massachusetts, Minnesota, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hairy Cell Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06561360's enrollment target sits among peer trials
86 4th of 15 higher than 12 of 15 other Hairy Cell Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hairy Cell Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
RECRUITING · Phase 2
-
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
RECRUITING · Phase 2
-
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
RECRUITING · Phase 2
-
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI